Breast Cancer

The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.

Ko Un “Clara” Park, MD discusses the assessment of robot-assisted nipple sparing mastectomy in breast cancer.

Erin Frances Cobain, MD, on second-line treatment options for patients with HR-positive, HER2-negative metastatic breast cancer.

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide an in-depth analysis of the randomized phase III monarchE trial, which focused on Abemaciclib in high-risk early-stage HR+, HER2- breast cancer, offering insights into recurrence rates, progression-free survival, and distant disease-free survival outcomes for patients.

Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.

Carlos Arteaga, MD, discusses the resistance to CDK4/6 inhibitors in estrogen receptor–positive breast cancer.

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, examine the NCCN guidelines compared to real-world evidence, particularly in the treatment of menopausal, pre-menopausal, and high-risk early-stage HR+/HER2- patients.

Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.

The FDA has accepted a biologics license application for datopotamab deruxtecan in HR-positive, HER2-negative metastatic breast cancer.

Reshma L. Mahtani, DO, discusses how attempts to address unmet needs in breast cancer have evolved over time.

Utidelone injectable has received FDA orphan drug designation for patients with breast cancer brain metastases.

Incorporating the Breast Cancer Index test assay into practice affected clinicians’ decision to offer endocrine therapy in HR+ early-stage disease.

Laura Spring, MD, and Manali Bhave, MD, highlight promising new systemic treatment options on the horizon for patients with metastatic breast cancer, including T-DM1 for HER2-low disease, the AKT inhibitor capivasertib, and novel endocrine therapies.

Laura Spring, MD, and Manali Bhave, MD, discuss sequencing approved antibody-drug conjugates, T-DM1 and sacituzumab govitecan, for hormone receptor-positive, HER2-low metastatic breast cancer after progression on chemotherapy.

Capivasertib plus fulvestrant has been approved in Japan for pretreated, PIK3CA-, AKT1-, or PTEN-altered, HR-positive, HER2-negative breast cancer.

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, discuss the biological and pathological risk factors influencing breast cancer development, treatment, and risk stratification.

Don S. Dizon, MD, on the prevalence of sexual complications in patients with breast cancer.

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.

Adjuvant atezolizumab did not provide a clinical benefit when added to chemotherapy in patients with triple-negative breast cancer.

Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.

Henry Kuerer, MD, PhD, FACS, CMQ, on significant advancements in neoadjuvant systemic therapies in breast cancer treatment

Ribociclib plus a nonsteroidal aromatase inhibitor bested nonsteroidal aromatase inhibitor therapy alone in terms of iDFS in early-stage breast cancer.

The FDA has approved safety label changes for fluorouracil products to include information regarding the agent’s use in patients with DPD.

Oncologists discuss considerations for systemic therapy selection beyond first-line endocrine-based regimens in recurrent hormone receptor-positive, HER2-low metastatic breast cancer, including use of additional endocrine therapy combinations, chemotherapy, and supportive care approaches.

Laura Spring, MD, and Manali Bhave, MD, discuss considerations for systemic therapy selection in a patient with recurrent hormone receptor-positive, HER2-low breast cancer, including use of plasma and tissue genomic testing and endocrine therapy sequencing based on factors like prior response and ESR1 mutation status.

Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.

Liquid nitrogen–based cryoablation elicited a 5-year local RFS rate of 96.39% in patients with low-risk, early-stage breast cancer.

Reshma Mahtani, DO, spotlights the challenges women in oncology may face throughout their careers and gives some advice to those just starting out.